| Literature DB >> 23993168 |
Julie Vignisse1, Harry W M Steinbusch2, Vladimir Grigoriev3, Alexei Bolkunov3, Alexey Proshin3, Lucien Bettendorff4, Sergey Bachurin5, Tatyana Strekalova2.
Abstract
Bifunctional drug therapy targeting distinct receptor signalling systems can generate increased efficacy at lower concentrations compared to monofunctional therapy. Non-competitive blockade of the NMDA receptors or the potentiation of AMPA receptors is well documented to result in memory enhancement. Here, we compared the efficacy of the low-affinity NMDA receptor blocker memantine or the positive modulator of AMPA receptor QXX (in C57BL/6J at 1 or 5mg/kg, ip) with new derivatives of isothiourea (0.5-1 mg/kg, ip) that have bifunctional efficacy. Low-affinity NMDA blockade by these derivatives was achieved by introducing greater flexibility into the molecule, and AMPA receptor stimulation was produced by a sulfamide-containing derivative of isothiourea. Contextual learning was examined in a step-down avoidance task and extinction of contextual memory was studied in a fear-conditioning paradigm. Memantine enhanced contextual learning while QXX facilitated memory extinction; both drugs were effective at 5 mg/kg. The new derivative IPAC-5 elevated memory scores in both tasks at the dose 0.5 mg/kg and exhibited the lowest IC₅₀ values of NMDA receptor blockade and highest potency of AMPA receptor stimulation. Thus, among the new drugs tested, IPAC-5 replicated the properties of memantine and QXX in one administration with increased potency. Our data suggest that a concomitant manipulation of NMDA- and AMPA-receptors results in pro-cognitive effects and supports the concept bifunctional drug therapy as a promising strategy to replace monofunctional therapies with greater efficacy and improved compliance.Entities:
Keywords: Low-affinity NMDA receptor blockade; Mouse; Multi-target mechanism; Positive modulation of AMPA receptor
Mesh:
Substances:
Year: 2013 PMID: 23993168 DOI: 10.1016/j.euroneuro.2013.06.010
Source DB: PubMed Journal: Eur Neuropsychopharmacol ISSN: 0924-977X Impact factor: 4.600